The Inovia resource library

Endpoints, estimands, TPPs and pivotal readiness.

Evidence regulators accept, from design to submission.

Comparators that survive regulatory scrutiny.

From gap list to tactics: plans that drive decisions.

What to do after an ambiguous readout.

Evidence strategy for early-stage biotechs, in order.

2026 edition. Our annual study of how RWE is actually used in FDA and EMA submissions, and what gets accepted.

How long evidence planning actually takes across biotech, by company stage and program type.

What a month of slippage actually costs, by development phase. The case for moving sooner, quantified.

The 5 things evidence leads need to know each month: regulatory moves, RWE developments and what they mean. Sign up below.